I-Mab Biopharma April 2024 Investor Presentation

I-Mab Biopharma is a NASDAQ-listed global biotech company with an innovative immunology-focused pipeline including CD73, CLDN18.2, and PD-L1 programs. Following the divestiture of its China operations in April 2024, the company maintains a strong balance sheet of $321.8M and is strategically focused on its most promising programs.